Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

JAMA

Volumn 279, Issue 18, 1998, Pages

  Walsh, Brian W ^a   Kuller, Lewis H ^b   Wild, Robert A ^c   Paul, Sofia ^d   Farmer, Mildred ^e   Lawrence, Jeffry B ^d   Shah, Aarti S ^d   Anderson, Pamela W ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e ICSL Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ESTROGEN; FIBRINOPEPTIDE A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROTHROMBIN; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMATOLOGICAL PARAMETERS; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

EID: 2642712522     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.18.1445     Document Type: Article

References (35)

1. Col NF, Eckman MH, Karss RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997; 277:1140-1147.
2. Johannes CB, Crawford SL, Posner JG, McKinlev SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol. 1994;140:439-452.
3. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-856.
4. McDonald CC, Stewart HJ, for the Scottish Breast Cancer Committee. Fatal myocardia infarction in the Scottish adjuvant tamoxifen trial. BMJ. 1991;303:435-437.
5. Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85: 1398-1406.
6. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-452.
7. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspect. 1995;8: 531-539.
8. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 1996;273:1222-1225.
9. Grese TA, Cho S, Finley DR, et al. Structure-activity relationships of selective-estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem. 1997;40: 146-167.
10. Anzano MA, Peer CW, Smith JM, et al. Chemo-prevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoie acid. J Natl Cancer Inst. 1996;88:123-125.
11. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causinguterine hypertrophy in ovariectomized rats. J Clin Invest. 1994;93:63-69.
12. Bryant HU, Black LJ, Rowley ER, et al. Raloxifene (LY139481 HCl): bone, lipid and uterine effects in the ovariectomized rat model. J Bone Miner Res. 1993;8(suppl 1):S123.
13. Bjarnason N, Haarbo J, Byrjalsen I, Kauffman R, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation. 1997;96:1964-1969.
14. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther. 1997;280:146-153.
15. Draper MW, Flowers DE, Huster WJ, Neild JA. Effects of raloxifene (LY139481) HCl on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: Christiansen C, Riis B, eds. Proceedings 1993: Fourth International Symposium on Osteoporosis and Consensus Development Conference. Aalborg Denmark: Handelstrykkeriet Aalborg ApS; 1993:119-121.
16. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY 139481) HCl: impact on bone turnover and serum lipid profile in healthy, postmenopausal women. J Bone Miner Res. 1996;11:835-842.
17. Delmas PD, Bjarnason NH, Mitlak BH, et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium. N Engl J Med. 1997;337:1641-1647.
18. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991; 325:1196-1204.
19. Willett WC, Sampson L, Browne ML, et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol. 1988; 127:188-199.
20. Trinder P. Oxidase determination of plasma cholesterol as cholest-4-en-3-one using iso-octane extraction. Ann Clin Biochem. 1981;18:64-70.
21. Marcovina SM, Levine DM, Lippi G. Lipoprotein(a):structure, measurement and clinical significance. In: Rifai N, Warnick GR, eds. Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC: AACC Press;. 1994:239-242.
22. Stein EA, Myers GL. Lipids, lipoproteins, and apolipoproteins. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia, Pa: WB Saunders Co; 1994:1085.
23. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992; 68:392-395.
24. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its fast inhibitor in plasma. Clin Chem. 1986;32:482-485.
25. 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
26. Soria J, Soria C, Ryckewaert JJ. A solid phase immunoenzymological assay for the measurement of human fibrinopeptide A. Thromb Res. 1980;20: 425-435.
27. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information J. 1991;25:411-424.
28. Efron B, Stein C. The jackknife estimate of variance. Ann Stat. 1981;9:586-596.
29. The Writing Group for the PEPI Trial. Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
30. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravistatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
31. Kannel WB, Wolf PA, Castelli WP, d'Augustino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-1186.
32. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal Postmenopausal women. J Clin Endocrinol Metab. 1995;80:3191.
33. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronisi U. Effect of tamoxifen on measurements of hemostasis in healthy postmenopausal women. Arch Intern Med. 1996;156: 1806-1810.
34. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994;14:1586-1593.
35. Constantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997; 89:776-782.